More News! Alzheimer’s treatment, gene therapies, fruit-based bioplastic and more…

Try as we might, we can’t cover all the cool biotech news out there! Here’s a roundup of what didn’t make the cut over the last week.

Regulations and funding

  • Cell Mogrify received €490,966 in funding from government backed Innovate UK to help progress the UK biotech’s cell therapy pipeline.
  • UK-based Evox Therapeutics was awarded  €1.75 Million from Innovate UK to develop its exosome therapy targeting a rare metabolic disease.
  • Transgene, a French immunotherapy biotech, has secured a €20M loan from French investment bank Natixis to develop its cancer and infectious disease therapies.
  • Probiodrug and the Alzheimer’s Disease Cooperative Study in the US have secured a grant worth €13.2M to run a phase II trial of the German biotech’s drug for treating mild Alzheimer’s.
  • Pfizer has secured a 15% share of French liver gene therapy company Vivet Therapeutics for €45M, with which it is working on a treatment for Wilson disease, with an exclusive option to acquire the whole company for up to €560M at a later date.
  • Deinove, an industrial and medical biotech based in France, announced its robotic extraction and screening platform for testing bacteria for antibiotic activity is now live, triggering a €1.5M payment from Bpifrance.

Products and services


  • The Mutation Analysis Facility at Karolinska University Hospital in Sweden has launched a range of sequencing services for clients across Europe to support precision medicine research and clinical decision making.

Clinical trials

  • Swedish biotech Alligator Bioscience presented promising early stage results for its candidate anti-cancer antibody aimed at treating metastasizing cancer.
  • UK-based Arecor has the go ahead to begin a phase I clinical trial for its ultra-fast acting insulin in Austria.
  • Morphosys and Chinese I-Mab Biopharma have started a phase II trial of Morphosys’s investigational antibody treatment for multiple myeloma in Taiwan, triggering a €4.4M milestone payment to the German biotech.
  • UK-based Trizell has launched a phase III trial of its gene therapy for malignant pleural mesothelioma, an aggressive form of lung cancer.
  • Dutch biotech Modra Pharmaceuticals has started a phase II trial of its treatment for metastatic breast cancer, a less toxic, more patient friendly formulation of well known cancer drug docetaxel.


  • Oxford BioDynamics is collaborating with Imperial College London to develop new methods of screening for prostate cancer.


  • A Swedish researcher has managed to make a prototype edible bioplastic out of orange and apple waste.
  • Algae capsules containing immune cells called macrophages could help prevent limb amputation in people with circulation problems by increasing blood flow to at-risk areas.

Images via E. Resko

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.